Relmada In-Licenses Psilocybin Program from Arbormentis

Share this

Relmada In-Licenses Psilocybin Program from Arbormentis


  • Arbormentis to receive $51M upfront in cash and equity in addition to $150M as milestone related to pre-specified development and commercialization milestones along with royalties on any commercialized therapy resulting from the collaboration
  • Relmada acquires the development & commercial rights for psilocybin and derivate program from Arbormentis in all Ex-Asia countries- including the US & EU. Additionally- companies collaborate to develop new therapies targeting neurological and psychiatric disorder
  • Relmada’s REL-1017 is currently in P-III trial for depression & results is expected from the human abuse potential study for REL-1017 in July’21

  | Ref: PRNewswire | Image: Relmada

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions